Fundación Socolinsky Centro de Vacunación Proteger - Recoleta
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cahn, Pedro E
UNITY, NCT05597735: Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Recruiting
3
480
Europe, RoW
Tecovirimat, Placebo
ANRS, Emerging Infectious Diseases, University Hospital, Geneva, Oswaldo Cruz Foundation, Fundacion Huesped, Buenos Aires, Argentina
Monkeypox, Mpox
09/25
11/26
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting
3
171
Europe, Canada, US, RoW
DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
10/25
10/26
NCT05005156: Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.

Recruiting
2b
876
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Fundación Huésped, Canadian Center for Vaccinology, CanSino Biologics Inc., Hospital Fernandez
Covid19
09/22
09/22
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Completed
2
22
Europe, Canada, US, RoW
VH4524184, Placebo
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/24
06/24
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection

Recruiting
2
150
Europe, Canada, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline
Hepatitis B
01/27
05/27
NCT05797662: A Study of Propranolol to Treat Kaposi Sarcoma

Not yet recruiting
2
25
RoW
Propranolol
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma
08/28
08/29
angley, Joanne M
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
3
44247
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
08/21
10/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cahn, Pedro E
UNITY, NCT05597735: Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Recruiting
3
480
Europe, RoW
Tecovirimat, Placebo
ANRS, Emerging Infectious Diseases, University Hospital, Geneva, Oswaldo Cruz Foundation, Fundacion Huesped, Buenos Aires, Argentina
Monkeypox, Mpox
09/25
11/26
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting
3
171
Europe, Canada, US, RoW
DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
10/25
10/26
NCT05005156: Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.

Recruiting
2b
876
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Fundación Huésped, Canadian Center for Vaccinology, CanSino Biologics Inc., Hospital Fernandez
Covid19
09/22
09/22
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Completed
2
22
Europe, Canada, US, RoW
VH4524184, Placebo
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/24
06/24
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection

Recruiting
2
150
Europe, Canada, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline
Hepatitis B
01/27
05/27
NCT05797662: A Study of Propranolol to Treat Kaposi Sarcoma

Not yet recruiting
2
25
RoW
Propranolol
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma
08/28
08/29
angley, Joanne M
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
3
44247
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
08/21
10/22

Download Options